Chronic Myelocytic Leukemia (CML) - Market Insight, Epidemiology and Market Forecast - 2027

Chronic Myelocytic Leukemia (CML) - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU: DIMI0262
  • Single User License
    (20% Off)
    $6,250.00
    $5000
  • Site License
    (30% Off)
    $12,500.00
    $8750
  • Global License
    (40% Off)
    $18,750.00
    $11250
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Chronic Myelocytic Leukemia  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Myelocytic Leukemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic Myelocytic Leukemia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Chronic Myelocytic Leukemia - Disease Understanding and Treatment Algorithm
According to American Cancer Society, Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells - the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen.
The DelveInsight Chronic Myelocytic Leukemia market report gives the thorough understanding of the Chronic Myelocytic Leukemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Chronic Myelocytic Leukemia in the US, Europe, and Japan.

Chronic Myelocytic Leukemia Epidemiology 
The Chronic Myelocytic Leukemia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Phase Specific Prevalence, Age Specific Prevalence, Gender Specific Prevalence and Diagnosed and treatable population] scenario of Chronic Myelocytic Leukemia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Surveillance, Epidemiology, and End Results (SEER) program, Chronic myeloid leukemia represents 0.5% of all new cancer cases in the U.S. and the number of new cases of chronic myeloid leukemia was 1.8 per 100,000 men and women per year based on 2011-2015 cases

Chronic Myelocytic Leukemia Drug Chapters
This segment of the Chronic Myelocytic Leukemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Gleevec, Sprycel, Tasigna, Bosulif, Iclusig and Synribo, etc. are approved marketed drugs for CML. Imatinib (Gleevec) was the first drug to specifically target the BCR-ABL tyrosine kinase protein, and it quickly became the standard treatment for CML patients. Bosulif, Iclusig and Synribo drugs are targeted towards patients doesn’t respond to first or second generation Tyrosine Kinase Inhibitors and provide option for additional lines of therapy.

Chronic Myelocytic Leukemia Market Outlook
The Chronic Myelocytic Leukemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
There are different potential drug candidates in late phase of development and their expected launch will create a huge impact on the CML market.  ABL001 (Novartis Pharmaceuticals), PF-114 (Fusion Pharma LLC) and Ponatinib (Ariad Pharmaceuticals) etc. may enter the CML market in the study period from 2016-2027.

Chronic Myelocytic Leukemia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Myelocytic Leukemia Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Chronic Myelocytic Leukemia Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Chronic Myelocytic Leukemia Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic Myelocytic Leukemia market

• Organize sales and marketing efforts by identifying the best opportunities for Chronic Myelocytic Leukemia market

• To understand the future market competition in the Chronic Myelocytic Leukemia market.

1. Report Introduction
2. Chronic Myelocytic Leukemia Market Overview at a Glance
2.1. 7 Major Market Size of Chronic Myelocytic Leukemia in 2017
2.2. 7 Major Market Size of Chronic Myelocytic Leukemia in 2027
3. Disease Background and Overview: Chronic Myelocytic Leukemia 
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
4.3. Phase specific prevalence of Chronic Myelocytic Leukemia disease
4.4. Age specific prevalence of Chronic Myelocytic Leukemia disease
4.5. Gender specific prevalence of Chronic Myelocytic Leukemia disease
4.6. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5. Chronic Myelocytic Leukemia: Country- Wise Epidemiology
5.1. United States
5.1.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.1.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.1.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.1.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.1.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.2. EU-5
5.2.1. Germany
5.2.1.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.2.1.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.2.1.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.2.1.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.2.1.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.2.2. France
5.2.2.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.2.2.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.2.2.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.2.2.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.2.2.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.2.3. Italy
5.2.3.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.2.3.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.2.3.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.2.3.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.2.3.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.2.4. Spain
5.2.4.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.2.4.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.2.4.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.2.4.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.2.4.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.2.5. United Kingdom
5.2.5.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.2.5.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.2.5.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.2.5.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.2.5.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
5.3. Japan
5.3.1. Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
5.3.2. Phase specific prevalence of Chronic Myelocytic Leukemia disease
5.3.3. Age specific prevalence of Chronic Myelocytic Leukemia disease
5.3.4. Gender specific prevalence of Chronic Myelocytic Leukemia disease
5.3.5. Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia
6. Treatment & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drugs
7.1. Bosulif: Pfizer
7.1.1. Product Description
7.1.2. Mechanism of action
7.1.3. Regulatory milestones
7.1.4. Other Development Activities
7.1.5. Safety and Efficacy
7.1.6. Advantages and Disadvantages
7.1.7. Product Profile
7.2. Iclusig: ARIAD Pharmaceuticals
7.2.1. Product Description
7.2.2. Mechanism of action
7.2.3. Regulatory milestones
7.2.4. Other Development Activities
7.2.5. Safety and Efficacy
7.2.6. Advantages and Disadvantages
7.2.7. Product Profile
7.3. Synribo: Teva Pharmaceuticals
7.3.1. Product Description
7.3.2. Mechanism of action
7.3.3. Regulatory milestones
7.3.4. Other Development Activities
7.3.5. Safety and Efficacy
7.3.6. Advantages and Disadvantages
7.3.7. Product Profile
To be continued in the report...
8. Emerging Therapies
8.1. Key Cross Competition
8.2. ABL001: Novartis Pharmaceuticals
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. PF-114: Fusion Pharma LLC  
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase
8.4. Ponatinib: Ariad Pharmaceuticals
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
To be continued in the report…
9. Chronic Myelocytic Leukemia Market Size
9.1. Key Findings
9.2. Total 7MM Chronic Myelocytic Leukemia Market Analysis 
9.2.1. Overview of Total Chronic Myelocytic Leukemia Market 
9.2.2.  Market size of Chronic Myelocytic Leukemia Market by 7MM (2016-2027)
10. 7MM Chronic Myelocytic Leukemia: Country-Wise Market Analysis
10.1. United States
10.1.1. Total Market Size of Chronic Myelocytic Leukemia
10.1.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.2. Germany
10.2.1. Total Market Size of Chronic Myelocytic Leukemia
10.2.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.3. France
10.3.1. Total Market Size of Chronic Myelocytic Leukemia
10.3.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.4. United Kingdom
10.4.1. Total Market Size of Chronic Myelocytic Leukemia
10.4.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.5. Spain
10.5.1. Total Market Size of Chronic Myelocytic Leukemia
10.5.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.6. Italy
10.6.1. Total Market Size of Chronic Myelocytic Leukemia
10.6.2. Market Size of Chronic Myelocytic Leukemia by Therapies
10.7. Japan
10.7.1. Total Market Size of Chronic Myelocytic Leukemia
10.7.2. Market Size of Chronic Myelocytic Leukemia by Therapies
11. Report Methodology
11.1. Sources Used
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Table 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Table 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Table 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Table 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Table 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Table 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Table 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Table 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Table 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Table 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Table 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Table 41 ABL001, Clinical Trials by Recruitment status, 2018
Table 42 ABL001, Clinical Trials by Zone, 2018
Table 43 PF-114, Clinical Trials by Recruitment status, 2018
Table 44 PF-114,Clinical Trials by Zone, 2018
Table 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Table 46 Ponatinib ,Clinical Trials by Zone, 2018
Table 47 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 Italy Market Size in USD, Million (2016-2027)
Table 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 United Kingdom Market Size in USD, Million (2016-2027)
Table 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Figure 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Figure 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Figure 10 Diagnosed and Treatable Cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Figure 11 Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 12 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 13 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 14 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Germany (2016-2027)
Figure 15 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Germany (2016-2027)
Figure 16 Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 17 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 18 Age specific prevalence  of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 19 Gender specific prevalence of Chronic Myelocytic Leukemia disease in France (2016-2027)
Figure 20 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in France (2016-2027)
Figure 21 Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 22 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 23 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 24 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Italy (2016-2027)
Figure 25 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Italy (2016-2027)
Figure 26 Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 27 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 28 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 29 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Spain (2016-2027)
Figure 30 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Spain (2016-2027)
Figure 31 Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 32 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 33 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 34 Gender specific prevalence of Chronic Myelocytic Leukemia disease in the UK (2016-2027)
Figure 35 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in the UK (2016-2027)
Figure 36 Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 37 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 38 Age specific prevalence  of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 39 Gender specific prevalence of Chronic Myelocytic Leukemia disease in Japan (2016-2027)
Figure 40 Diagnosed and Treatable cases of Chronic Myelocytic Leukemia in Japan (2016-2027)
Figure 41 ABL001, Clinical Trials by Recruitment status, 2018
Figure 42 ABL001, Clinical Trials by Zone, 2018
Figure 43 PF-114, Clinical Trials by Recruitment status, 2018
Figure 44 PF-114,Clinical Trials by Zone, 2018
Figure 45 Ponatinib, Clinical Trials by Recruitment status, 2018
Figure 46 Ponatinib ,Clinical Trials by Zone, 2018
Figure 47 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 Italy Market Size in USD, Million (2016-2027)
Figure 57 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 United Kingdom Market Size in USD, Million (2016-2027)
Figure 61 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 2 7 MM Phase Specific Prevalent cases of Chronic Myelocytic Leukemia (2016-2027)
Table 3 7MM Age specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 4 7MM Gender specific prevalence  of Chronic Myelocytic Leukemia disease (2016-2027)
Table 5 7MM Diagnosed and Treatable cases of Chronic Myelocytic Leukemia (2016-2027)
Table 6 Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 7 Phase Specific Prevalent cases of Chronic Myelocytic Leukemia in the US (2016-2027)
Table 8 Age specific prevalence  of Chronic Myelocytic Leukemia disease in the US (2016-2027)
Table 9 Gender specific prevalence of Chronic Myelocytic Leukemia disease